TGTX - TG Therapeutics Inc Stock Price, Fair Value and News

13.63USD+0.31 (+2.33%)Delayed as of 30 Apr 2024, 12:23 pm ET

Market Summary

USD13.63+0.31

Delayedas of 30 Apr 2024, 12:23 pm

2.33%

TGTX Stock Price

View Fullscreen

TGTX RSI Chart

TGTX Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

162.32

Price/Sales (Trailing)

8.8

EV/EBITDA

79.73

Price/Free Cashflow

-65.48

TGTX Price/Sales (Trailing)

TGTX Profitability

EBT Margin

5.59%

Return on Equity

7.9%

Return on Assets

3.84%

Free Cashflow Yield

-1.53%

TGTX Fundamentals

TGTX Revenue

Revenue (TTM)

233.7M

Rev. Growth (Yr)

54.9K%

Rev. Growth (Qtr)

-73.48%

TGTX Earnings

Earnings (TTM)

12.7M

Earnings Growth (Yr)

72.8%

Earnings Growth (Qtr)

-112.65%

Breaking Down TGTX Revenue

52 Week Range

7.6335.67

(Low)(High)

Last 7 days

-5.5%

Last 30 days

-12.4%

Last 90 days

-17.6%

Trailing 12 Months

-46.4%

How does TGTX drawdown profile look like?

TGTX Financial Health

Current Ratio

5.92

Debt/Equity

0.62

Debt/Cashflow

-0.31

TGTX Investor Care

Shares Dilution (1Y)

5.51%

Diluted EPS (TTM)

0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.6M	24.1M	189.8M	233.7M
2022	7.9M	7.0M	5.0M	2.8M
2021	907.0K	2.4M	4.4M	6.7M
2020	152.0K	152.0K	152.0K	152.0K
2019	337.0K	152.0K	152.0K	152.0K
2018	224.8K	297.5K	370.3K	443.0K
2017	283.1K	240.5K	231.5K	152.0K
2016	229.4K	290.5K	322.5K	323.0K
2015	86.9K	118.8K	150.7K	182.6K
2014	36.9K	42.9K	49.0K	55.0K
2013	53.5K	87.5K	120.6K	30.8K
2012	0	0	0	92.1K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of TG Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	lonial sagar	sold	-79,675	15.935	-5,000	-
Mar 12, 2024	charney laurence n	sold	-351,340	15.97	-22,000	-
Jan 06, 2024	weiss michael s	acquired	-	-	1,001,910	ceo
Jan 05, 2024	power sean a	acquired	-	-	75,000	cfo
Jan 05, 2024	charney laurence n	sold	-333,025	19.03	-17,500	-
Jan 03, 2024	power sean a	sold	-809,431	16.91	-47,867	cfo
Dec 15, 2023	power sean a	gifted	-	-	-40,000	cfo
Sep 28, 2023	hoberman kenneth	acquired	-	-	20,000	-
Sep 28, 2023	echelard yann	acquired	-	-	20,000	-
Sep 28, 2023	lonial sagar	sold	-	-	-20,000	-

Which funds bought or sold TGTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	Signature Wealth Management Partners, LLC	unchanged	-	-20,158	163,964	0.13%
Apr 26, 2024	Clear Creek Financial Management, LLC	added	2.58	-28,579	301,919	0.04%
Apr 26, 2024	First Horizon Advisors, Inc.	unchanged	-	-65.00	532	-%
Apr 26, 2024	UMB Bank, n.a.	sold off	-100	-13,596	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-6.24	-1,335,070	6,755,090	-%
Apr 25, 2024	Lindbrook Capital, LLC	reduced	-8.95	-2,527	10,830	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-12.8	-831,000	2,887,000	-%
Apr 25, 2024	Valeo Financial Advisors, LLC	reduced	-31.53	-475,215	605,949	0.02%
Apr 25, 2024	nVerses Capital, LLC	new	-	65,403	65,403	0.16%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	reduced	-15.75	-143,938	432,375	-%

Are Funds Buying or Selling TGTX?

Are funds buying TGTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TGTX

No. of Funds

Unveiling TG Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	darwin global management, ltd.	2.7%	4,046,598	SC 13G/A
Feb 13, 2024	vanguard group inc	9.03%	13,670,944	SC 13G/A
Jan 26, 2024	blackrock inc.	7.1%	10,768,163	SC 13G/A
Jan 25, 2024	state street corp	5.45%	8,253,573	SC 13G/A
Apr 03, 2023	darwin global management, ltd.	7.1%	10,451,241	SC 13G
Feb 09, 2023	vanguard group inc	10.67%	15,502,764	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 03, 2023	state street corp	7.17%	10,415,161	SC 13G/A
Feb 01, 2023	blackrock inc.	6.3%	9,132,890	SC 13G/A
Oct 11, 2022	vanguard group inc	10.15%	14,746,392	SC 13G/A

Recent SEC filings of TG Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 18, 2024	PRE 14A	PRE 14A
Mar 15, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	144	Notice of Insider Sale Intent
Mar 12, 2024	144	Notice of Insider Sale Intent
Feb 29, 2024	10-K	Annual Report
Feb 28, 2024	8-K	Current Report

Peers (Alternatives to TG Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

TG Therapeutics Inc News

Latest updates

TG Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-73.5%	43,970,500	165,815,000	16,074,000	7,803,000	80,000	95,000	594,000	2,016,000	2,321,000	2,030,000	1,545,000	793,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000	38,000
Costs and Expenses	10.6%	56,456,000	51,031,000	-	-	-	35,057,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	60,748,000	44,795,000	52,143,000	35,057,000	39,535,000	68,888,000	95,269,000	87,158,000	79,036,000	89,995,000	86,820,000	85,760,000	50,883,000	50,283,000	37,998,000	60,899,000	35,582,000	34,727,000	54,188,000
S&GA Expenses	-4.9%	31,153,500	32,769,000	30,715,000	28,068,000	22,505,000	14,254,000	12,638,000	20,609,000	32,412,000	34,899,000	34,017,000	26,762,000	43,859,000	35,296,000	14,434,000	14,261,000	7,055,500	2,914,000	2,716,000	2,342,000	1,912,500
R&D Expenses	18.3%	17,448,000	14,753,000	28,122,000	15,870,000	29,635,000	20,801,000	26,874,000	48,042,000	62,646,500	51,967,000	44,871,000	63,094,000	42,961,000	50,464,000	36,449,000	36,022,000	30,943,500	57,985,000	32,866,000	32,385,000	52,275,500
EBITDA Margin	-	0.11	-	-0.55	-1.60	-4.98	-3.11	-2.33	-2.23	-2.76	-4.14	-7.34	-18.90	-117	-	-	-	-	-	-	-	-
Interest Expenses	-34.5%	2,431,000	3,713,000	3,627,000	2,844,000	2,862,000	1,648,000	3,017,000	2,664,000	1,079,000	1,038,000	1,623,000	1,898,000	1,290,500	1,610,000	2,228,000	1,201,000	1,899,000	1,537,000	1,077,000	774,000	220,000
EBT Margin	-	0.06	-	-1.01	-2.84	-8.74	-4.85	-3.50	-3.08	-3.64	-5.53	-10.09	-26.85	-160	-	-	-	-	-	-	-	-
Net Income	-112.7%	-14,416,000	113,930,000	-47,610,000	-39,232,000	-52,994,000	-35,818,000	-40,510,000	-69,013,000	-93,338,500	-85,637,000	-78,497,000	-90,628,000	-88,218,000	-87,163,000	-52,884,000	-51,116,000	-39,572,500	-61,930,000	-36,212,000	-35,156,000	-53,860,000
Net Income Margin	139.7%	0.05	-0.14	-7.30	-19.66	-71.22	-47.49	-41.44	-41.26	-52.04	-77.84	-142	-351	-	-	-	-	-	-	-	-	-
Free Cashflow	-Infinity%	-13,210,000	-	-42,008,000	-59,905,000	-23,873,000	-34,499,000	-49,116,000	-68,696,000	-86,989,000	-67,280,000	-60,344,000	-81,422,000	-52,181,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.4%	330	331	221	197	194	218	252	303	380	410	481	549	626	274	295	102	163	93.00	107	118	84.00
Current Assets	-0.4%	318	319	209	185	168	183	203	242	331	372	455	535	612	260	281	88.00	149	80.00	94.00	105	79.00
Cash Equivalents	-38.4%	93.00	151	97.00	61.00	102	110	147	186	299	327	402	472	553	254	261	52.00	114	45.00	57.00	64.00	43.00
Inventory	18.7%	40.00	34.00	30.00	27.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-28.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	1.7%	169	166	180	170	135	117	123	133	142	98.00	98.00	103	106	103	100	103	124	119	93.00	98.00	60.00
Current Liabilities	-6.9%	54.00	58.00	73.00	63.00	53.00	36.00	43.00	55.00	65.00	88.00	88.00	92.00	88.00	78.00	68.00	63.00	84.00	80.00	56.00	61.00	39.00
Long Term Debt	1.2%	100	99.00	98.00	97.00	71.00	71.00	69.00	67.00	67.00	-	-	-	8.00	15.00	22.00	29.00	29.00	29.00	29.00	28.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	1.00	16.00	23.00	30.00	22.00	15.00	7.00	-	-	-	-	-	-
LT Debt, Non Current	1.2%	100	99.00	98.00	97.00	71.00	71.00	69.00	67.00	67.00	-	-	-	8.00	15.00	22.00	29.00	29.00	29.00	29.00	28.00	-
Shareholder's Equity	-2.6%	161	165	40.00	27.00	59.00	100	129	170	237	312	383	445	519	171	194	-	39.00	-	13.00	19.00	24.00
Retained Earnings	-1.0%	-1,514	-1,500	-1,613	-1,566	-1,527	-1,500	-1,400	-1,400	-1,328	-1,235	-1,149	-1,100	-980	-892	-805	-752	-701	-661	600	-563	-528
Additional Paid-In Capital	0.6%	1,675	1,665	1,654	1,594	1,586	1,575	1,567	1,568	1,566	1,547	1,533	1,517	1,500	1,063	1,000	751	740	636	613	583	553
Shares Outstanding	0.0%	151	151	151	149	146	135	135	134	132	132	132	132	-	-	-	-	-	-	-	-	-
Float	-	-	-	3,400	-	-	-	564	-	-	-	4,936	-	-	-	2,163	-	-	-	688	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-115.8%	-13,210	83,704	-42,005	-59,902	-23,870	-34,495	-49,116	-68,689	-86,909	-67,201	-60,169	-81,355	-52,026	-56,532	-43,834	-62,115	-30,393	-33,202	-35,860	-33,351	-33,690
Share Based Compensation	2.2%	9,385	9,184	12,541	6,823	11,058	7,000	-1,000	2,121	14,356	14,000	16,300	16,618	33,505	28,300	7,400	11,068	6,487	1,300	800	1,882	1,454
Cashflow From Investing	-48.1%	-44,755	-30,229	30,501	-6,168	16,269	-2,990	10,379	-43,671	3,288	-631	-2,475	-514	-52,076	14,911	11,205	1,450	4.00	-44.00	457	-1,135	238
Cashflow From Financing	-100.2%	-1.00	421	47,047	25,238	49.00	275	135	-850	55,997	-7,361	-7,162	-55.00	403,389	35,265	241,092	81.00	98,354	20,695	28,284	56,880	4,694

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TGTX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Revenue	$ 233,662	$ 2,785	$ 6,689
Costs and expenses:
Cost of revenue	14,131	265	790
Research and development:
Noncash compensation	13,010	13,224	24,047
Other research and development	63,182	112,128	198,532
Total research and development	76,192	125,352	222,579
Selling, general and administrative:
Noncash compensation	24,923	5,961	37,227
Other selling, general and administrative	97,783	64,046	90,863
Total selling, general and administrative	122,706	70,007	128,090
Total costs and expenses	213,029	195,624	351,459
Operating income (loss)	20,633	(192,839)	(344,770)
Other expense (income):
Interest expense	12,615	10,191	5,638
Other income	(5,044)	(4,695)	(2,307)
Total other expense (income), net	7,571	5,496	3,331
Net income (loss) before taxes	13,062	(198,335)	(348,101)
Income taxes	390	0	0
Net income (loss)	$ 12,672	$ (198,335)	$ (348,101)
Net income (loss) per common share:
Basic (in dollars per share)	$ 0.09	$ (1.46)	$ (2.63)
Diluted (in dollars per share)	$ 0.09	$ (1.46)	$ (2.63)
Weighted-average shares outstanding:
Basic (in shares)	141,955,112	135,411,258	132,222,753
Diluted (in shares)	148,508,465	135,411,258	132,222,753
Product [Member]
Revenue:
Revenue	$ 92,005	$ 2,633	$ 6,537
License [Member]
Revenue:
Revenue	$ 141,657	$ 152	$ 152

TGTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	175,000,000	175,000,000
Current assets:
Cash and cash equivalents	$ 92,933	$ 102,304
Short-term investment securities	124,575	59,374
Accounts receivable, net	51,093	0
Inventories	39,823	0
Prepaid research and development	4,183	4,237
Other current assets	5,336	2,359
Total current assets	317,943	168,274
Restricted cash	1,285	1,273
Long-term investment securities	0	12,404
Right of use assets	8,050	8,888
Leasehold interest, net	1,415	1,627
Equipment, net	95	307
Goodwill	799	799
Total assets	329,587	193,572
Current liabilities:
Accounts payable and accrued expenses	38,471	42,019
Other current liabilities	1,631	1,169
Lease liability – current portion	1,446	1,581
Accrued compensation	12,172	8,432
Total current liabilities	53,720	53,201
Deferred revenue	6,016	305
Loan payable	100,118	71,135
Lease liability – non-current	9,231	10,344
Total liabilities	169,085	134,985
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value per share (175,000,000 shares authorized, 151,465,598 and 146,426,697 shares issued, 151,424,289 and 146,385,388 shares outstanding at December 31, 2023 and December 31, 2022, respectively	151	146
Additional paid-in capital	1,674,946	1,585,708
Treasury stock, at cost, 41,309 shares at December 31, 2023 and December 31, 2022	(234)	(234)
Accumulated deficit	(1,514,361)	(1,527,033)
Total stockholders’ equity	160,502	58,587
Total liabilities and stockholders’ equity	$ 329,587	$ 193,572

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

CEO	Mr. Michael S. Weiss Esq.
WEBSITE	tgtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	244

TG Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for TG Therapeutics Inc? What does TGTX stand for in stocks?

TGTX is the stock ticker symbol of TG Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TG Therapeutics Inc (TGTX)?

As of Mon Apr 29 2024, market cap of TG Therapeutics Inc is 2.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TGTX stock?

You can check TGTX's fair value in chart for subscribers.

What is the fair value of TGTX stock?

You can check TGTX's fair value in chart for subscribers. The fair value of TG Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TG Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TGTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TG Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TGTX is over valued or under valued. Whether TG Therapeutics Inc is cheap or expensive depends on the assumptions which impact TG Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TGTX.

What is TG Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, TGTX's PE ratio (Price to Earnings) is 162.32 and Price to Sales (PS) ratio is 8.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TGTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on TG Therapeutics Inc's stock?

In the past 10 years, TG Therapeutics Inc has provided 0.097 (multiply by 100 for percentage) rate of return.